Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 5:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Sunitinib Clear all
Active, not recruiting Phase 2 Interventional

Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma

NCT02068586
View directory record Official record
Conditions
Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size, Iris Melanoma, Stage I Intraocular Melanoma, Stage IIA Intraocular Melanoma, Stage IIB Intraocular Melanoma, Stage IIIA Intraocular Melanoma, Stage IIIB Intraocular Melanoma, Stage IIIC Intraocular Melanoma, Stage I Uveal Melanoma AJCC V7, Stage II Uveal Melanoma AJCC V7, Stage III Uveal Melanoma AJCC V7
Interventions
Sunitinib, Valproic Acid, Sunitinib Malate, Sunitinib Malate + Valproic Acid
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 15, 2026 · Synced Sep 17, 2026, 5:17 PM EDT
Completed Phase 1 Interventional

A Phase I Study of SUNITINIB and Rapamycin in Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT00555256
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
sunitinib and rapamycin (Drug will be held)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 5, 2016 · Synced Sep 17, 2026, 5:17 PM EDT
Completed Not applicable Interventional Results available

High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia

NCT02551718
View directory record Official record
Conditions
Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Refractory Acute Leukemia of Ambiguous Lineage
Interventions
Chemosensitivity Assay, Cytology Specimen Collection Procedure, Gene Expression Analysis, Genetic Variation Analysis, In Vitro Sensitivity-Directed Chemotherapy
Other · Genetic · Drug
Lead sponsor
University of Washington
Other
Eligibility
3 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 29, 2022 · Synced Sep 17, 2026, 5:17 PM EDT
Terminated Phase 2 Interventional Results available

Sunitinib Malate in Treating Patients With Recurrent Transitional Cell Bladder Cancer

NCT01118351
View directory record Official record
Conditions
Recurrent Bladder Cancer, Transitional Cell Carcinoma of the Bladder
Interventions
sunitinib malate, immunohistochemistry staining method, TdT-mediated dUTP nick end labeling assay, light microscopy, laboratory biomarker analysis
Drug · Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 30, 2019 · Synced Sep 17, 2026, 5:17 PM EDT
Terminated Not applicable Interventional Results available

Sunitinib Malate Related Fatigue in Patients With Metastatic Kidney Cancer

NCT01740154
View directory record Official record
Conditions
Fatigue, Recurrent Renal Cell Cancer, Stage IV Renal Cell Cancer
Interventions
transcranial magnetic stimulation, electromyography, survey administration, sunitinib malate
Procedure · Other · Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 5, 2018 · Synced Sep 17, 2026, 5:17 PM EDT
Completed Phase 2 Interventional Results available

A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) as Monotherapy or in Combination With Bevacizumab (Avastin®) Compared to Sunitinib (Sutent®) in Participants With Untreated Advanced Renal Cell Carcinoma

NCT01984242
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody, Bevacizumab, Sunitinib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
25
States / cities
Scottsdale, Arizona • Duarte, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2019 · Synced Sep 17, 2026, 5:17 PM EDT
Completed Phase 1 Interventional

A Study To Find The Best Doses Of SU011248 And Gemcitabine When Given Together To Patients With Advanced Solid Tumors

NCT00615446
View directory record Official record
Conditions
Solid Tumors
Interventions
SU011248; Gemcitabine
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 29, 2010 · Synced Sep 17, 2026, 5:17 PM EDT
Completed Phase 2 Interventional Results available

A Study Of SU011248 As Therapy In Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer

NCT00113516
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
carboplatin, paclitaxel, sunitinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
27
States / cities
Los Angeles, California • Newark, Delaware • Wilmington, Delaware + 17 more
Source: ClinicalTrials.gov public record
Updated May 17, 2010 · Synced Sep 17, 2026, 5:17 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V)

NCT06390826
View directory record Official record
Conditions
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Radionuclide Imaging, Sunitinib
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 17, 2026, 5:17 PM EDT
Terminated Phase 1 Interventional

A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma

NCT02386111
View directory record Official record
Conditions
Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms, Neoplasms, Neoplasms by Histologic Type, Clear-cell Metastatic Renal Cell Carcinoma
Interventions
Combination of varlilumab and sunitinib
Drug
Lead sponsor
Celldex Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
9
States / cities
Birmingham, Alabama • Sacramento, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2018 · Synced Sep 17, 2026, 5:17 PM EDT
Terminated Phase 1 Interventional

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

NCT03878524
View directory record Official record
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8, Anemia, Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Castration-Resistant Prostate Carcinoma, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid System Neoplasm, Locally Advanced Pancreatic Adenocarcinoma, Metastatic Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Pancreatic Adenocarcinoma, Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Primary Myelofibrosis, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Hematologic Malignancy, Recurrent Hodgkin Lymphoma, Recurrent Myelodysplastic Syndrome, Recurrent Myelodysplastic/Myeloproliferative Neoplasm, Recurrent Myeloproliferative Neoplasm, Recurrent Non-Hodgkin Lymphoma, Recurrent Plasma Cell Myeloma, Recurrent Small Lymphocytic Lymphoma, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Refractory Chronic Lymphocytic Leukemia, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Chronic Myelomonocytic Leukemia, Refractory Hematologic Malignancy, Refractory Hodgkin Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Myelodysplastic Syndrome, Refractory Myelodysplastic/Myeloproliferative Neoplasm, Refractory Non-Hodgkin Lymphoma, Refractory Plasma Cell Myeloma, Refractory Primary Myelofibrosis, Refractory Small Lymphocytic Lymphoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8, Unresectable Pancreatic Adenocarcinoma
Interventions
Abemaciclib, Abiraterone, Afatinib, Bevacizumab, Bicalutamide, Biospecimen Collection, Bortezomib, Cabazitaxel, Cabozantinib, Capecitabine, Carboplatin, Celecoxib, Cobimetinib, Copanlisib, Dabrafenib, Dacomitinib, Darolutamide, Dasatinib, Doxorubicin, Durvalumab, Enasidenib, Entrectinib, Enzalutamide, Erlotinib, Everolimus, Fluorouracil, Idelalisib, Imatinib, Ipilimumab, Lenvatinib, Leucovorin, Lorlatinib, Losartan, Nab-paclitaxel, Neratinib, Nivolumab, Olaparib, Oxaliplatin, Palbociclib, Panobinostat, Pembrolizumab, Pertuzumab, Ponatinib, Quality-of-Life Assessment, Regorafenib, Ruxolitinib, Sirolimus, Sorafenib, Sunitinib, Trametinib, Trastuzumab Emtansine, Tretinoin, Vemurafenib, Venetoclax, Vismodegib, Vorinostat
Drug · Biological · Procedure + 1 more
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
21 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 3, 2024 · Synced Sep 17, 2026, 5:17 PM EDT
Recruiting Phase 2 Interventional

Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment

NCT06955169
View directory record Official record
Conditions
Intracranial Meningioma
Interventions
[177Lu]Lu-DOTATATE, Standard of Care treatments
Drug · Other
Lead sponsor
RTOG Foundation, Inc.
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
16
States / cities
Irvine, California • La Jolla, California • New Haven, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 17, 2026, 5:17 PM EDT
Completed Not applicable Interventional Results available

Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET/CT and DCE MRI

NCT00537056
View directory record Official record
Conditions
Kidney Neoplasms, Carcinoma, Renal Cell, Kidney (Renal Cell) Cancer
Interventions
FDG PET CT, DCE MRI, F-18 Fluoro-deoxi-glucose, Gadolinium-DTPA, Sunitinib
Procedure · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 13, 2017 · Synced Sep 17, 2026, 5:17 PM EDT
Completed Phase 3 Interventional Results available

Study Of Sunitinib In Combination With Docetaxel Vs Docetaxel In Patients With Advanced Breast Cancer

NCT00393939
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Sunitinib malate, Taxotere
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
594 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
8
States / cities
Berkely, California • Shreveport, Louisiana • Beaumont, Texas + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2012 · Synced Sep 17, 2026, 5:17 PM EDT
Completed Phase 2 Interventional Results available

Study Tests The Safety And Effectiveness Of SU011248 In Patients With Non-Small Cell Lung Cancer Having Brain Metastases

NCT00372775
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Sunitinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
17
States / cities
Norwalk, Connecticut • Cocoa Beach, Florida • Merritt Island, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2011 · Synced Sep 17, 2026, 5:17 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Sunitinib, Cyclophosphamide, and Methotrexate in Treating Patients With Metastatic Breast Cancer

NCT00616122
View directory record Official record
Conditions
Breast Cancer
Interventions
cyclophosphamide, methotrexate, sunitinib malate, laboratory biomarker analysis
Drug · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 120 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 12, 2020 · Synced Sep 17, 2026, 5:17 PM EDT
Completed No phase listed Observational

Non-Interventional Retrospective Correlation Of Tumor Mutational Status To Clinical Benefit Of GIST Patients Treated With Sunitinib

NCT01459757
View directory record Official record
Conditions
GIST
Interventions
non-interventional
Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
322 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
12
States / cities
Duarte, California • Washington D.C., District of Columbia • Gainesville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2013 · Synced Sep 17, 2026, 5:17 PM EDT
Completed Phase 2 Interventional Results available

Sunitinib in Treating Patients With Locally Recurrent or Metastatic Kidney Cancer

NCT00459875
View directory record Official record
Conditions
Kidney Cancer
Interventions
sunitinib malate
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 25, 2015 · Synced Sep 17, 2026, 5:17 PM EDT
Completed Not applicable Interventional Results available

Exploratory Study of Sunitinib Malate as a Component of Neoadjuvant Therapy for Breast Cancer

NCT00656669
View directory record Official record
Conditions
Breast Cancer
Interventions
sunitinib alone, sunitinib plus paclitaxel, doxorubicin and cyclophosphamide
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 22, 2023 · Synced Sep 17, 2026, 5:17 PM EDT
Completed Phase 1 Interventional

A Study To Find The Best Doses Of SU011248 (Sunitinib) And Capecitabine When These Drugs Are Administered Together

NCT00618124
View directory record Official record
Conditions
Solid Tumors, Breast Cancer, Neoplasms
Interventions
SU011248; Capecitabine
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
3
States / cities
Indianapolis, Indiana • Albuqurque, New Mexico • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 2, 2010 · Synced Sep 17, 2026, 5:17 PM EDT
Completed Phase 1 Interventional Results available

Study Of Sunitinib Plus FOLFOX In Patients With Solid Tumors

NCT00599924
View directory record Official record
Conditions
Colorectal Neoplasms, Neoplasms
Interventions
sunitinib + FOLFOX
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
3
States / cities
Aurora, Colorado • Nashville, Tennessee • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 14, 2015 · Synced Sep 17, 2026, 5:17 PM EDT
Terminated Phase 1 Interventional

Sunitinib, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck

NCT00906360
View directory record Official record
Conditions
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Salivary Gland Squamous Cell Carcinoma, Stage III Salivary Gland Cancer, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Nasopharynx, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage III Verrucous Carcinoma of the Larynx, Stage III Verrucous Carcinoma of the Oral Cavity, Stage IV Salivary Gland Cancer, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx, Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IV Verrucous Carcinoma of the Larynx, Stage IV Verrucous Carcinoma of the Oral Cavity, Tongue Cancer, Untreated Metastatic Squamous Neck Cancer With Occult Primary
Interventions
sunitinib malate, pharmacological study, 3-dimensional conformal radiation therapy, cetuximab
Drug · Other · Radiation + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
12
States / cities
Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2013 · Synced Sep 17, 2026, 5:17 PM EDT
Active, not recruiting Phase 3 Interventional

Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma

NCT05678673
View directory record Official record
Conditions
Non-Clear Cell Renal Cell Carcinoma
Interventions
XL092, Nivolumab, Sunitinib Malate
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
317 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
10
States / cities
Duarte, California • Newport Beach, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 17, 2026, 5:17 PM EDT
Terminated Phase 1Phase 2 Interventional

A Phase I/II Study of Sunitinib and Dacarbazine

NCT00496223
View directory record Official record
Conditions
Melanoma
Interventions
Sunitinib, Dacarbazine
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 22, 2011 · Synced Sep 17, 2026, 5:17 PM EDT